New data on emerging immunotherapies and fresh findings about established agents are likely to dominate clinical and marketplace news from this year's Annual Meeting of the ASCO, according to industry analysts.
New data on emerging immunotherapies and fresh findings about established agents are likely to dominate clinical and marketplace news from this year’s Annual Meeting of the American Society of Clinical Oncology (ASCO), according to industry analysts.
Approximately 30,000 oncology specialists are expected to attend the 49th annual conference, which opened Friday and runs through Tuesday at McCormick Place in Chicago, Illinois.
Kantar Health, which conducts market research and product development for the pharmaceutical industry, has identified approximately 12 abstracts with practice-changing potential that, based on preliminary data, are expected to emerge from the more than 4500 abstracts presented at the meeting. Those abstracts are discussed in the “OBR Conference Preview,” available at the OBR oncology information site (http://goo.gl/7VQl5). The abstracts are:
For the pharmaceutical industry, ASCO marks an important occasion to showcase its research to clinicians and investors alike. Many companies have announced research they intend to spotlight, including:
ASCO has posted most of the abstracts on its website at http://goo.gl/OxnJv. Late-breaking research will be added to the online library after presentation.